Smartleaf Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Smartleaf Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.6K	Buy	1,132 +304	+37%	+$5.04K	﹤0.01%	2065
2025 Q4	$15.7K	Buy	828 +759	+1,100%	+$10.9K	﹤0.01%	2160
2025 Q3	$640	Buy	69 +16	+30%	+$166	﹤0.01%	2819
2025 Q2	$616	Sell	53 -162	-75%	-$1.75K	﹤0.01%	2554
2025 Q1	$2.61K	Sell	215 -513	-70%	-$8.58K	﹤0.01%	2398
2024 Q4	$13.6K	Sell	728 -53	-7%	-$1.22K	﹤0.01%	1863
2024 Q3	$18K	Buy	781 +764	+4,494%	+$17.3K	﹤0.01%	1402
2024 Q2	$352	Buy	+17	New	+$265	﹤0.01%	2614

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Smartleaf Asset Management's NRIX Position: Q1 2026 in Review

Smartleaf Asset Management increased its Nurix Therapeutics (NRIX) stake by 37% in Q1 2026, buying an estimated $5.04K and bringing the position to 1,132 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Smartleaf Asset Management first reported a position in NRIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $18K in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Smartleaf Asset Management held 1,132 shares of Nurix Therapeutics worth $16.6K as of Q1 2026.
Smartleaf Asset Management bought 304 Nurix Therapeutics shares in Q1 2026, an estimated $5.04K.
Nurix Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2065 holding.
Smartleaf Asset Management first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 8 quarters since.
Smartleaf Asset Management's Nurix Therapeutics position peaked at $18K in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.